5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Alnylam ( ALNY ) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2% YoY to $3.71B driven by AMVUTTRA. Kymera ( KYMR ) has surged 204.3% over the past year on its targeted protein degradation platform with up to $750M in potential Gilead payments, Arcus ( RCUS ) targets a $5B+ peak sales opportunity with its HIF-2a inhibitor showing 45.2% ORR in Phase 1, and Sarepta ( SRPT ) trades at a historically rare 0.978x price-to-sales discount with ELEVIDYS as the only approved gene therapy for ambulatory DMD patients. Large pharmaceutical companies are racing to acquire biotech platforms addressing patent cliffs and next-generation therapeutic mechanisms, with depressed valuations across these five names creating attractive entry points for strategic buyers seeking RNAi, protein degradation, and gene therapy exposure. A recent study identified one single habit that doubled Americans' retirement savings and moved retirement from dream, to reality. Read more here
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management [Yahoo! Finance]Yahoo! Finance
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension ManagementBusiness Wire
- Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (ALNY) had its "buy" rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.MarketBeat
- Alnylam Pharmaceuticals (ALNY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.MarketBeat
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- ALNY's page on the SEC website